Abstract

A REVIEW OF (COVID-19) CORONAVIRUS DISEASE-2019 MANAGEMENT STRATEGIES FOR COVID-19: AND THEIR SUCCESS RATE

*Tulika Srivastava, Shrashti Jain, Sushma Pal, Farhad Mehta and Deepti Jain

ABSTRACT

COVID-19 is an ailment, that is produced by a novel coronavirus currently known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; in previously identified as 2019-nCoV), which was at first found in Wuhan, China, during an epidemic of respiratory ailment patients. It was first announced to the World Health Organization on December 31, 2019. On 30/01/20, The COVID-19 pandemic had been announced a worldwide health crisis by WHO. This disease was announced a worldwide outbreak by the WHO on 11/03/20. Here is a summary of current clinical features data on COVID-19 prevention, diagnosis, therapies, and a novel COVID-19 emergency medicine that has been approved. We have gathered information from numerous research reports, WHO guidelines, and other sources. It's crucial to remind readers that fresh data on clinical characteristics, diagnoses, management strategies, and outcomes is updated practically every hour. COVID-19 is a virus that infects people. It was announced as a worldwide health crisis because this disease has an extreme high potential to spread. Despite COVID-19's worsening trends, no medicines have been approved as having considerable clinical efficacy. According to the studies, Remdesivir(antiviral drug) was found to be the most effective; as this works, reducing RNA-dependent RNA polymerase activity (RdRp). The therapeutic effectiveness of remdesivir was found as 200 mg on first day, followed by 100 mg once day is currently being reviewed in a large-scale trial. Favipiravir, another powerful anti-influenza RdRp inhibitor, is too being clinically tested in COVID-19 patients. Other option is hydroxychloroquine given 200 mg twice daily combined azithromycin, 500 mg first day, then 250 mg one time daily on days 2e5, exhibited wonderful clinical effectiveness and antiSARS- CoV-2 effectiveness in vitro in COVID-19 patients. Monoclonal and Polyclonal antibodies are being considered as a remedy of SARS-CoV-2. DCGI has permitted 2-deoxy-D-glucose (2-DG) as an emergency treatment.

Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Remdesivir; Hydroxychloroquine; 2-deoxy-D-glucose (2-DG); Verafin; Treatment.